Test Price
2,800 AED✅ Home Collection Available
COG8 Gene Sequencing (CDG Type 2H) in UAE | AED 2,800 | DHA-Licensed Laboratory
Executive Summary & Core Metrics
This advanced NGS-based genetic test provides 99.9% diagnostic sensitivity for congenital disorder of glycosylation type 2H, backed by ISO 9001:2015‑certified processing, premium home collection, and strict adherence to UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited laboratory.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (8 AM – 11 PM daily).
- Clinical Guidance: Complimentary telephonic post‑test result interpretation.
- Insurance Support: Direct billing verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The COG8 NGS test sequences the entire COG8 gene to detect pathogenic variants responsible for congenital disorder of glycosylation type 2H, a rare autosomal recessive condition primarily affecting neurological development. Full coding regions plus ±10 bp flanking intronic sequences are analyzed on the Illumina® platform, with orthogonal Sanger confirmation of all clinically significant variants.
| Feature | Our COG8 NGS Test | Closest Alternative |
|---|---|---|
| Precision | Single‑gene full coding region with ±10 bp flanking intronic analysis | Multi‑gene CDG panel – may omit COG8 or analyze only select exons |
| Methodology | NGS (Illumina® platform) with orthogonal Sanger confirmation of all variants | NGS panel without single‑gene focus or confirmatory sequencing |
| Turnaround Time | 3 – 4 weeks | 4 – 6 weeks (varies by laboratory) |
| Regulatory Compliance | ISO 9001:2015, DHA‑licensed facility, UAE PDPL | May lack full ISO or local DHA accreditation |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specialist, I recognize the diagnostic complexity surrounding rare glycosylation disorders. The COG8 sequencing test provides a definitive molecular resolution when clinical presentation strongly suggests CDG type 2H. However, results must be correlated with neurological examination, biochemical markers, and family history. A confirmed pathogenic variant warrants structured genetic counseling to address recurrence risks and multidisciplinary care planning."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Safety Notice
Do not discontinue any prescribed medication or alter your treatment plan without first consulting your physician. Genetic test results inform long‑term management and are not a substitute for acute clinical judgment. Always follow your treating specialist's recommendations regarding medications and therapies.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Acute neurological deterioration, suspected metabolic crisis, or inability to provide informed consent. This test is not intended for emergency diagnosis.
- Emergency Red Flags: Sudden loss of consciousness, new‑onset seizures, severe difficulty breathing, or inability to swallow. Seek immediate emergency medical attention.
Patient FAQ & Clinical Guidance
1. What does the COG8 gene test detect?
The COG8 NGS test identifies DNA variants in the COG8 gene causing congenital disorder of glycosylation type 2H, a rare neurological syndrome that affects development, motor function, and cognition.
2. How is the sample collected for this test?
A certified phlebotomist performs a painless whole‑blood draw during a VIP home visit, or you can provide a dried blood spot on an FTA card. Both methods follow temperature‑controlled cold‑chain logistics for specimen integrity.
3. How soon will I receive the results?
Results are typically ready within 3 to 4 weeks, and include a telephonic clinical guidance session led by a certified genetic counselor to explain the findings in plain language.
4. Is genetic counseling available after the test?
Yes, every report includes a complimentary telephonic consultation with a qualified genetic specialist to discuss implications, recurrence risks, and next steps for family planning or clinical management.
5. Can this test be done for children or infants?
Yes, with appropriate consent from a parent or legal guardian. The sample volume required for infants is minimal and can be collected via a gentle heel‑prick or venous draw depending on clinical suitability.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data, genetic results, and personal identifiers are encrypted, access‑controlled, and processed under strict confidentiality agreements. Clinical safety and patient consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License Number 1143 and operates under ISO 9001:2015 certification.
Clinical & Logistical Metadata
| Test Name | COG8 Gene Sequencing (CDG Type 2H) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | NGS (Illumina® Platform) + Sanger Confirmation |
| ICD-10-CM Code | E77.8 |
| LOINC Code | 21665-9 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians